Cargando…

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis

INTRODUCTION: Erythropoiesis-stimulating agents are associated with increased cardiovascular risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis are at higher risk for morbidity and mortality. Systematic evaluation of this population was predefined in the roxad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G., Zhong, Ming, Lee, Tyson T., Houser, Mark T., Frison, Lars, Houghton, John, Little, Dustin J., Peony Yu, Kin-Hung, Neff, Thomas B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938204/ https://www.ncbi.nlm.nih.gov/pubmed/33732976 http://dx.doi.org/10.1016/j.ekir.2020.12.018

Ejemplares similares

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
por: Provenzano, Robert, et al.
Publicado: (2022)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2023)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study
por: Moussa, Oumarou, et al.
Publicado: (2022)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
por: Zhang, Yaling, et al.
Publicado: (2021)

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2021)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
por: Zhang, Yangyang, et al.
Publicado: (2023)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
por: Shutov, Evgeny, et al.
Publicado: (2021)

The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
por: Zhang, Li, et al.
Publicado: (2021)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2022)

Short-term effects of roxadustat on serum copper and iron changes in a peritoneal dialysis patient
por: Nakamura, Hironori, et al.
Publicado: (2022)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
por: Ichii, Mitsuru, et al.
Publicado: (2021)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease
por: Zhang, Yanjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bkfn5j7mb0ojl2ogjhd66ts0og